Brown Sydney E S, Meyer Michael, Meyer Andrea, Cassidy Ruth, Zhao Xinyi, Wagner Deborah, Wetzel Laura, Colquhoun Douglas A
Department of Anesthesiology University of Michigan, Ann Arbor, MI, USA.
Division of Pediatric Anesthesiology Department of Anesthesiology University of Michigan, Ann Arbor, MI, USA.
Anesthesiol Res Pract. 2024 Aug 24;2024:6049114. doi: 10.1155/2024/6049114. eCollection 2024.
Sugammadex vials were fractionated into 25, 50, or 100 mg aliquots, which would be distributed to anesthesia staff by pharmacy staff in approximate 2 mg/kg of actual body weight doses (±10%). We analyzed changes in sugammadex waste and dosing practices 1/1/2019 to 3/15/2023 pre/postintervention (4/1/2021). We gauged dose appropriateness using last train of four (TOF) prior to sugammadex administration.
7,889 patients 2-17 years (4,771 with documented TOF), ASA 1-4 receiving general anesthesia with a steroidal NMB medication and sugammadex reversal. Pre- and postintervention mean doses were 2.5 mg/kg (SD: 1.2) and 2.4 mg/kg (SD: 0.96), respectively. A smaller proportion of cases received standard 2 or 4 mg/kg doses (pre: 77.6 vs. post: 66.7%). Mean waste per case declined from 4.2 mg/kg (SD: 4.1) to 0.22 mg/kg (SD: 0.38). Among cases with 0 or 1 measured twitches on TOF that should receive at least 4 mg/kg, fewer received at least 3.6 mg/kg (post: 56.7% vs. pre: 66.8%), and a greater proportion received less than 2.2 mg/kg (post: 27.4% vs. pre: 20.7%). Among cases that should have received at least 2 mg/kg by TOF, the proportion of patients receiving more than 3.6 mg/kg declined from 9.5% to 5.2%. . Fractionating sugammadex vials was associated with decreases in waste, but not dose, and significant underdosing was more likely to occur. While vial fractionation could enable increased access to sugammadex and other costly medications, it may introduce unintended consequences.
将舒更葡糖小瓶分成25毫克、50毫克或100毫克的等分试样,药房工作人员将按实际体重约2毫克/千克的剂量(±10%)分发给麻醉人员。我们分析了2019年1月1日至2023年3月15日干预前/后(2021年4月1日)舒更葡糖浪费情况和给药方法的变化。我们在给予舒更葡糖之前使用四个成串刺激(TOF)的最后一个刺激来评估剂量是否合适。
7889例2至17岁患者(4771例有记录的TOF),ASA 1至4级,接受全身麻醉,使用甾体类神经肌肉阻滞剂药物并采用舒更葡糖进行逆转。干预前和干预后的平均剂量分别为2.5毫克/千克(标准差:1.2)和2.4毫克/千克(标准差:0.96)。接受标准2或4毫克/千克剂量的病例比例较小(干预前:77.6%,干预后:66.7%)。每例的平均浪费量从4.2毫克/千克(标准差:4.1)降至0.22毫克/千克(标准差:0.38)。在TOF上有0或1次可测颤搐且应至少接受4毫克/千克剂量的病例中,接受至少3.6毫克/千克剂量的病例较少(干预后:56.7%,干预前:66.8%),且接受少于2.2毫克/千克剂量的病例比例更高(干预后:27.4%,干预前:20.7%)。在TOF显示应至少接受2毫克/千克剂量的病例中,接受超过3.6毫克/千克剂量的患者比例从9.5%降至5.2%。将舒更葡糖小瓶进行分样与浪费量减少相关,但与剂量无关,且更有可能出现明显的剂量不足情况。虽然小瓶分样可增加获取舒更葡糖和其他昂贵药物的机会,但可能会带来意想不到的后果。